
ADVB — Advanced Biomed Inc. Common Stock
NASDAQ · Healthcare · Diagnostics & Research
$10.44
+$0.99 (+10.48%)
Advanced Biomed Inc. Common Stock (ADVB) is a diagnostics & research company listed on NASDAQ. It is led by Yi Lu Ph.D., based in 122 East 42nd Street, New York, NY, United States, 10168, with about 40 employees. Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Net income was -$386.9K.
Use this ADVB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ADVB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ADVB SEC filings page. Lician reads the product cache first so this HTML stays unique to Advanced Biomed Inc. Common Stock even when a live quote feed is slow.
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
ADVB Key Statistics
Market Cap
$0.00M
Volume
586,907
Previous Close
$8.02
Day Range
$7.63 – $9.16
EPS
-$0.16
Revenue
$0.00
Net Income
-$3.26M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
40
ADVB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$3.26M | -$2.78M |
| EPS (Diluted) | -$0.16 | -$0.14 |
Total Assets
$6.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.90M
Operating Cash Flow
-$5.83M
Free Cash Flow
$0.00
Advanced Biomed Inc. Common Stock Company Information
- CEO & Chairman
- Yi Lu Ph.D.
- Headquarters
- 122 East 42nd Street, New York, NY, United States, 10168
- Website
- www.advanbiomed.com
- IPO / Founded
- 2025-03-06
- Sector
- Healthcare
- Industry
- Diagnostics & Research